Showing results (881-890 of 1,877) with videos related to
Sort By:
Pageof 188
Immunotherapy|September 27, 2023
Stability assessment of anti-bacterial antibodies in immunoglobulin G-depleted serum with validated immunoassaysAndrea Engelmaier, Harald A Butterweck, Alfred WeberImmunotherapy|September 4, 2023
PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomasVasiliki Siozopoulou, Evelien Smits, Karen Zwaenepoel, et al.Immunotherapy|June 9, 2023
Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitisNira A Krasnow, Donald F Chute, Ayo S Falade, et al.Immunotherapy|October 18, 2023
Infectious adverse events in patients with atopic dermatitis treated with baricitinibFlaminia Antonelli, Dalma Malvaso, Giacomo Caldarola, et al.Immunotherapy|June 20, 2023
A meta-analysis of application of PD-1/PD-L1 inhibitor-based immunotherapy in unresectable locally advanced triple-negative breast cancerWei Zhang, Yujing He, Yuning Tang, et al.Immunotherapy|June 20, 2023
Cancer immunotherapy via stem cell-derived NK cellsFatemeh Hosseini, Mohammad Ahmadvand, Roya Karimi, et al.Immunotherapy|March 10, 2026
MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancersPanagiotis J Vlachostergios, Konstatinos Evmorfopoulos, Konstantinos Marsitopoulos, et al.Immunotherapy|March 24, 2026
Evaluating pozelimab in the treatment of CHAPLE diseaseNecmiye Keser Ozturk, Durmus Burak Demirkaya, Alper Bulutoglu, et al.Immunotherapy|April 14, 2026
Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysisJiuli Zhou, Wenbo Tang, Liqiong XueImmunotherapy|April 21, 2026
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumabAli Kaan Güren, Nazım Can Demircan, Özge Gümüşay, et al.Pageof 188